The Predictive Value of Serum Inflammatory Markers for the Severity of Cervical Lesions

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2024 Jun 29

PMID 38943072

Authors

Lin Qin

Lina Zhang

Affiliations

Soon will be listed here.

Abstract

Objective: Exploring the predictive value of NLR, PLR, MLR, and SII for the severity of cervical cancer screening abnormalities in patients.

Methods: A retrospective analysis was conducted on the data of 324 patients suspected of cervical lesions due to abnormal TCT and/or HPV in our hospital from January 2023 to December 2023, who underwent colposcopy. The pathological results of colposcopic biopsy confirmed that there were 140 cases of chronic cervicitis, which classified as the group without cervical lesions. The cervical lesion group included 184 cases, including 91 cases of LSIL, 71 cases of HSIL, and 22 cases of cervical cancer. Compared the differences in preoperative peripheral blood NLR, PLR, MLR, and SII among different groups of patients, and evaluated their predictive value for the severity of cervical lesions using Receiver Operating Characteristic (ROC) curves.

Results: The levels of NLR, PLR, and SII in the group without cervical lesions were lower than those in the group with cervical lesions (p < 0.05), and there was no statistically significant difference in MLR (p > 0.05). The comparison of NLR among LSIL, HSIL, and cervical cancer groups showed statistically significant differences (p < 0.05), while PLR, MLR, and SII showed no statistically significant differences (p > 0.05). The AUC of peripheral blood NLR, PLR, and SII for predicting cervical lesions were 0.569, 0.582, and 0.572, respectively. The optimal cutoff values were 2.3,176.48, and 603.56. The sensitivity and specificity were 38.6% and 73.6%, 28.8% and 85.7%, 37.5% and 76.4%, respectively. At the same time, the joint testing of the three had the highest efficiency, with sensitivity of 69% and specificity of 45%.

Conclusion: Although the peripheral blood NLR, PLR, and SII of the cervical lesions patients were higher than those without cervical lesions in cervical cancer screening abnormal patients, the predictive ROC curve discrimination was low. Therefore, it is not recommended to use preoperative peripheral blood inflammatory markers as markers for cervical cancer screening abnormal patient diversion.

Citing Articles

Associations Between Preoperative Inflammatory Indices and Residual or Recurrent Cervical Intraepithelial Neoplasia Post Loop Electrosurgical Excision Procedure.

Zhai F, Mu S, Song Y, Zhang M, Zhang C, Lv Z J Inflamm Res. 2024; 17:8741-8751.

PMID: 39559397 PMC: 11571924. DOI: 10.2147/JIR.S485698.

References

Vitkauskaite A, Urboniene D, Celiesiute J, Jariene K, Skrodeniene E, Nadisauskiene R . Circulating inflammatory markers in cervical cancer patients and healthy controls. J Immunotoxicol. 2020; 17(1):105-109. DOI: 10.1080/1547691X.2020.1755397. View

Yildiz H, Deger M, Aslan G . Prognostic value of preoperative inflammation markers in non-muscle invasive bladder cancer. Int J Clin Pract. 2021; 75(6):e14118. DOI: 10.1111/ijcp.14118. View

Chen L, Kong X, Yan C, Fang Y, Wang J . The Research Progress on the Prognostic Value of the Common Hematological Parameters in Peripheral Venous Blood in Breast Cancer. Onco Targets Ther. 2020; 13:1397-1412. PMC: 7028387. DOI: 10.2147/OTT.S227171. View

Huang Y, Gao Y, Wu Y, Lin H . Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis. Cancer Cell Int. 2020; 20:499. PMC: 7552553. DOI: 10.1186/s12935-020-01590-4. View

Nahand J, Moghoofei M, Salmaninejad A, Bahmanpour Z, Karimzadeh M, Nasiri M . Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: A review. Int J Cancer. 2019; 146(2):305-320. PMC: 6999596. DOI: 10.1002/ijc.32688. View

Yin Y, Zhang Y, Li L, Zhang S, Liu N, Yuan S . Prognostic Value of Pretreatment Lymphocyte-to-Monocyte Ratio and Development of a Nomogram in Breast Cancer Patients. Front Oncol. 2022; 11:650980. PMC: 8719671. DOI: 10.3389/fonc.2021.650980. View

Olingy C, Dinh H, Hedrick C . Monocyte heterogeneity and functions in cancer. J Leukoc Biol. 2019; 106(2):309-322. PMC: 6658332. DOI: 10.1002/JLB.4RI0818-311R. View

Ji Y, Wang H . Prognostic prediction of systemic immune-inflammation index for patients with gynecological and breast cancers: a meta-analysis. World J Surg Oncol. 2020; 18(1):197. PMC: 7414550. DOI: 10.1186/s12957-020-01974-w. View

Huang Z, Fu Z, Huang W, Huang K . Prognostic value of neutrophil-to-lymphocyte ratio in sepsis: A meta-analysis. Am J Emerg Med. 2019; 38(3):641-647. DOI: 10.1016/j.ajem.2019.10.023. View

10.

Arbyn M, Weiderpass E, Bruni L, de Sanjose S, Saraiya M, Ferlay J . Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2019; 8(2):e191-e203. PMC: 7025157. DOI: 10.1016/S2214-109X(19)30482-6. View

11.

Huang H, Liu Q, Zhu L, Zhang Y, Lu X, Wu Y . Prognostic Value of Preoperative Systemic Immune-Inflammation Index in Patients with Cervical Cancer. Sci Rep. 2019; 9(1):3284. PMC: 6397230. DOI: 10.1038/s41598-019-39150-0. View

12.

Gao Y, Guo W, Cai S, Zhang F, Shao F, Zhang G . Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected esophageal squamous cell carcinoma. J Cancer. 2019; 10(14):3188-3196. PMC: 6603384. DOI: 10.7150/jca.30281. View

13.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

14.

Hu C, Bai Y, Li J, Zhang G, Yang L, Bi C . Prognostic value of systemic inflammatory factors NLR, LMR, PLR and LDH in penile cancer. BMC Urol. 2020; 20(1):57. PMC: 7251912. DOI: 10.1186/s12894-020-00628-z. View

15.

Tian T, Lu J, Zhao W, Wang Z, Xu H, Ding Y . Associations of systemic inflammation markers with identification of pulmonary nodule and incident lung cancer in Chinese population. Cancer Med. 2022; 11(12):2482-2491. PMC: 9189452. DOI: 10.1002/cam4.4606. View

16.

Zhang K, Hua Y, Wang D, Chen L, Wu C, Chen Z . Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer. J Transl Med. 2019; 17(1):30. PMC: 6339361. DOI: 10.1186/s12967-019-1782-x. View

17.

Zhu M, Feng M, He F, Han B, Ma K, Zeng X . Pretreatment neutrophil-lymphocyte and platelet-lymphocyte ratio predict clinical outcome and prognosis for cervical Cancer. Clin Chim Acta. 2018; 483:296-302. DOI: 10.1016/j.cca.2018.05.025. View

18.

Yang Q, Zhou Q, He X, Cai J, Sun S, Huang B . Retrospective analysis of the incidence and predictive factors of parametrial involvement in FIGO IB1 cervical cancer. J Gynecol Obstet Hum Reprod. 2021; 50(8):102145. DOI: 10.1016/j.jogoh.2021.102145. View

19.

Zhao M, Duan X, Mi L, Shi J, Li N, Yin X . Prognosis of hepatocellular carcinoma and its association with immune cells using systemic inflammatory response index. Future Oncol. 2022; 18(18):2269-2288. DOI: 10.2217/fon-2021-1087. View

20.

Taguchi A, Furusawa A, Ito K, Nakajima Y, Shimizuguchi T, Hara K . Postradiotherapy persistent lymphopenia as a poor prognostic factor in patients with cervical cancer receiving radiotherapy: a single-center, retrospective study. Int J Clin Oncol. 2020; 25(5):955-962. DOI: 10.1007/s10147-020-01623-y. View